![]() |
|
|
Vol. 295, Issue 1, 212-218, October 2000
Cardiovascular Diseases Research (P.C.W., E.J.C., R.M.K., R.P.M.,
C.A.W., A.M.S.), Chemical and Physical Sciences (M.L.Q., R.R.W.), Drug
Metabolism and Pharmacokinetics (M.R.W.), DuPont Pharmaceuticals
Company, Wilmington, Delaware
SK549 (mol. wt. 546 Da) is a synthetic, selective inhibitor of human
coagulation factor Xa (fXa) (Ki = 0.52 nM). This study compared the antithrombotic effects of SK549 and
a series of benzamidine isoxazoline fXa inhibitors with aspirin, DuP
714 (a direct thrombin inhibitor), recombinant tick anticoagulant
peptide, or heparin in a rabbit model of electrically induced carotid
arterial thrombosis. Compounds were infused i.v. continuously from 60 min before electrical stimulation to the end of the experiment. Values
of ED50 (dose that increases the carotid blood flow to 50%
of the control) were 0.12 µmol/kg/h for SK549, 0.56 µmol/kg/h for
aspirin, 0.14 µmol/kg/h for DuP 714, 0.06 µmol/kg/h for recombinant
tick anticoagulant peptide, and >100 U/kg/h for heparin. The
EC50 (plasma concentration that increased blood flow to
50% of the control) for SK549 was 97 nM. Unlike aspirin and heparin,
SK549 was efficacious and, at 1.5 µmol/kg/h i.v.
(n = 9), maintained carotid blood flow at 87 ± 6% of control level for greater than 90 min. Unlike heparin, SK549
inhibited ex vivo fXa activity but not ex vivo thrombin activity. There
was a highly significant correlation between
Ki (fXa) and ED50 of a series of
fXa inhibitors (r = 0.85, P < .001). Therefore, these results suggest that SK549 is a novel, potent, and effective antithrombotic agent in a rabbit model of arterial thrombosis. It is likely that SK549 exerts its antithrombotic effect
through selective inhibition of fXa. Furthermore, SK549 may be
clinically useful for the prevention of arterial thrombosis.
This article has been cited by other articles:
![]() |
P. C. Wong, E. J. Crain, C. A. Watson, A. M. Zaspel, M. R. Wright, P. Y. Lam, D. J. P. Pinto, R. R. Wexler, and R. M. Knabb Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 993 - 1000. [Abstract] [Full Text] [PDF] |
||||